Branded

RedHill's Talicia is the first and only FDA approved rifabutin-based H. pylori infection therapy.

Sanofi’s Fluzone High-Dose Quadrivalent is used in people age 65 and older, to protect against influenza A and B strains.

Biogen's and Alkermes' Vumerity is a new oral treatment option for relapsing forms of multiple sclerosis.

Baxdela now is approved to treat community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Amgen is making Repatha available at a reduced list price of $5,850 per year.

Fiasp, which was approved in 2017 for use by intravenous infusion or subcutaneous multiple daily injections, now is approved for use in insulin infusion pumps.

Janssen's Stelara now has Food and Drug Administration approval for six indications, most recently for adults with moderately to severely active ulcerative colitis.

Roche’s single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza.